Outcomes of systemic treatment in advanced melanoma after progression on anti–PD-1 therapy: a real-world study with literature review

INTRODUCTION: Currently, a substantial proportion of patients are still treated with first-line anti-PD-1 immunotherapy (ICI). After disease progression, treatment options, especially for patients with BRAF-negative tumors, are limited. One regimen used in real-world practice in this setting is ipil...

全面介紹

書目詳細資料

Principais autores:	Piotr J. Błoński, Krzysztof Ostaszewski, Barbara Buchalska, Julia Szymkiewicz, Tomasz Switaj, Paweł Rogala, Katarzyna Kozak, Monika Dudzisz-Śledź, Anna M. Czarnecka
格式:	Artigo
語言:	Inglês
出版:	Via Medica 2026-04-01
叢編:	Oncology in Clinical Practice
主題:	ipilimumab melanoma immunotherapy immune checkpoint inhibitors anti-CTLA-4
在線閱讀:	https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/111553
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!